Silica Corpora was born as a result of the main purpose of the founders, Timofei and Jaime, to respond to challenges in drug discovery exploiting recent advances in computational technologies.
Design, not discovery
The estimated cost of bringing a new prescription drug to the market has risen dramatically from $1.1B in 2003 to $2.3B in 2019 while early stages of drug discovery take around 3 years. The replacement of lead generation and lead optimization stages of antibody drug discovery with AI may reduce the times and costs of early antibody discovery by 10-100 times while improving its quality and accuracy.
"Our mission is to develop tailored AI-solutions to develop more-quality and more cost-effective antibody therapeutics, turning historical data of previous Drug Discovery projects into valuable assets, significantly reducing the prospective sunk costs."
Our expertise supports our results
Our Journey So Far
SILICA CORPORA IS FOUNDED
Jaime and Tim started the company when they received financing from REACT Scholarship, a Startup Incubator Berlin (SIB) program for health tech Start-ups.
In this stage, our platform can generate CDRs from scratch, given a target sequence and epitope. Moreover, the platform is capable of binding affinity optimization given sequences of a target and antibody candidates.